Peptides 101: What They Are and How to Think About Them

“Peptide” has turned into a wellness buzzword. But it isn’t a product, a brand, or a promise. It’s just a way to describe the shape of a molecule. Insulin is a peptide. So is a sketchy vial sold online with no testing behind it. The word by itself tells you nothing about whether something is safe, works, is legal, or is even worth your time. This page is the front door to Compound Codex: a calm, careful look at what peptides are, which ones are real medicine, where the gray market begins, and how to think clearly about the evidence for any one of them.

What a peptide actually is

A peptide is a short chain of amino acids — usually 2 to 50 of them — held together by chemical links called peptide bonds. Amino acids are the body’s basic building blocks, the same ones that make up proteins.

The difference between a “peptide” and a “protein” is mostly about length, and the dividing line is a little fuzzy. A common rule of thumb: chains of about 2 to 50 amino acids are peptides, and longer chains are proteins. You’ll also run into more specific words. A dipeptide has two amino acids, a tripeptide has three, an oligopeptide has a few, and a polypeptide has many. The easiest way to picture it is a sliding scale of size — amino acids build into peptides, which build into proteins — not three separate, unrelated groups.

Here’s the part worth repeating: “peptide” describes shape and size. It is not a safety rating, and it doesn’t mean something is an approved treatment.

How peptides work in the body

A lot of peptides act as hormones or signaling molecules — messengers that carry instructions from one part of the body to another. Peptide hormones love water and are usually too big or too charged to pass through the outer wall of a cell. So they tend to work as “first messengers”: they latch onto receptors on the outside surface of a cell instead of going inside it.

That latching-on kicks off chemical chain reactions inside the cell, often through G-protein-coupled receptors and so-called second messengers (helper molecules such as cAMP, cGMP, calcium, and others). The practical upshot is that peptide-hormone effects tend to kick in fast but not last long. This is different from steroid hormones, which dissolve in fat, slip right through the cell wall, and work more slowly by changing how genes behave.

The takeaway: peptides mostly act like keys cut for specific locks. That precision is exactly why you should be suspicious when someone claims a single peptide “heals everything.” A molecule built to fit a narrow set of locks isn’t likely to fix every unrelated problem at once.

The proven side: FDA-approved peptide drugs

There is a real, heavily studied side to all this, and it’s worth understanding — because it’s the credibility that the rest of the market borrows from.

Insulin was the first peptide hormone used as medicine. The first patient, Leonard Thompson, was treated in January 1922. His first dose caused an allergic reaction, and a cleaned-up second dose worked. The discovery earned a Nobel Prize in 1923. Decades later came Humulin — the first lab-made human insulin built using recombinant DNA technology (a method for copying human genes inside other cells to make a product). It was FDA-approved in October 1982, and it was the first approved medical product of any kind made that way.

Since then, more than 80 peptide drugs have been approved by the FDA. (You may see bigger global numbers, in the range of 120 to 140 — treat those as rough secondhand estimates, not a firm count.) The first FDA-approved peptide cancer drug, goserelin, was approved in late 1989 for advanced prostate cancer.

The most familiar modern peptide drugs are the GLP-1 receptor agonists — medicines that switch on a receptor for a gut hormone called GLP-1, which affects blood sugar and appetite. They’re the biggest current group:

Semaglutide — sold as Ozempic and Rybelsus for type 2 diabetes, and as Wegovy for long-term weight management.
Tirzepatide — a dual GIP/GLP-1 agonist (it acts on two of these gut-hormone receptors), sold as Mounjaro for type 2 diabetes and Zepbound for weight management.
Others include liraglutide, dulaglutide, exenatide, and lixisenatide.

Here’s what “peptide drug” means when it’s done right: years of clinical trials, real manufacturing standards, a prescription, and a known set of risks. That’s a very different thing from a vial bought online.

The gray market: “research use only” peptides

A lot of the peptides people talk about online are not approved drugs, and they’re not dietary supplements either. They’re sold with the label “Research Use Only” (RUO), often alongside phrases like “not for human consumption.”

RUO is a genuine regulatory category — it’s meant for lab products that haven’t been checked or approved for use in people. The standard label reads “For Research Use Only. Not for use in diagnostic procedures.” But here’s the part that matters: under FDA guidance, what makes something truly RUO is how it’s actually meant to be used, not what a seller prints on the label. A seller can’t dodge drug rules just by stamping “research use only” on a product they’re clearly marketing for people to inject.

In practice, that disclaimer works as a legal shield. It lets online sellers offer unapproved compounds — names you’ll see include BPC-157, TB-500, and various growth-hormone-releasing peptides — to customers who inject them anyway, with no pharmaceutical oversight, no enforced quality checks, no standard way of preparing them, and no doctor involved. Reporting on this space has documented unknown purity and contents, the risk of immune reactions and impurities, and no human safety or effectiveness data at all. Some unregulated products have even been found to contain contaminants such as arsenic and lead.

So the honest way to read “research use only” is this: it’s doing legal work, not safety work. It means the seller is flat-out not claiming the product is safe for you. We go deeper on this in The Gray Market and Research Use Only, Explained.

The regulatory picture is in flux

This area is changing, so it’s worth laying out carefully and putting a date on each fact.

In September 2023, the FDA placed a group of peptides into “Category 2” of its interim list of bulk drug substances for compounding under section 503A. (Compounding is when a pharmacy mixes or prepares a drug for a specific patient; this list governs which raw ingredients pharmacies may use that way.) The agency flagged these peptides as having real safety concerns that made them unsuitable for that use, pointing to issues like immune reactions, impurities, and limited human clinical data.

On the GLP-1 front, the FDA declared the semaglutide shortage resolved in February 2025. The temporary “enforcement-discretion” periods — stretches where the FDA chose not to crack down on pharmacies compounding these drugs during the shortage — came to an end: for 503A pharmacies in April 2025, and for 503B outsourcing facilities in May 2025. The tirzepatide discretion period also ended in 2025.

More recently — and this part is still unfolding — HHS Secretary Robert F. Kennedy Jr. said on a February 27, 2026 podcast that he is “a big fan” of peptides and claimed the FDA had “illegally reclassified 19 peptides” under the prior administration. That’s his political take, not a settled legal finding, and it should be read as a quote, not a fact. After that, on April 15, 2026, the FDA removed seven peptides from Category 2 and set them up for review by the Pharmacy Compounding Advisory Committee (PCAC): a July 23–24, 2026 meeting (covering BPC-157, KPV, TB-500, MOTS-c, DSIP, Semax, and Epitalon), with a second batch scheduled for review before the end of February 2027.

Two things are essential here so you don’t get misled. First, as of this writing (June 2026), the July meeting hasn’t happened and there’s no outcome yet — anyone predicting a result is guessing. Second, PCAC only gives advice. It can recommend something, but the FDA would still have to go through formal rulemaking to actually add anything to the 503A list. And even if something did get added, the most that would do is let compounding pharmacies dispense it with a prescription. It would not be a general FDA stamp of approval saying those peptides are safe and effective drugs. Several of these compounds have their own Ledger entries — see BPC-157, for example — where we track this one by one.

The sports and anti-doping angle

Peptide hormones, growth factors, related substances, and their mimics fall under category S2 of the World Anti-Doping Agency (WADA) Prohibited List. They’re banned at all times — both in and out of competition.

Banned examples include growth-hormone secretagogues (substances that prod the body to release more growth hormone, such as MK-677, ipamorelin, the GHRP series, hexarelin, and CJC-1295) and TB-500 / thymosin beta-4. The point for a newcomer is simple: many of the “wellness” peptides marketed so casually online are literally on the world anti-doping banned list. That’s a strong sign these are biologically active drugs, not harmless supplements. We cover this in Peptides and Anti-Doping.

Why the space is so hyped

The current wave is largely driven by social media. Influencers rebranded injectable peptides as “biohacking” for longevity, skin, sleep, healing, libido, and weight loss. By reported figures, the peptide hashtag has shown up on over 270,000 TikTok videos and over 654,000 Instagram posts, and U.S. peptide-related searches reportedly hit roughly 10 million in a single month in early 2026 (a big chunk of that GLP-1-related).

Two things fuel the hype. One is a real “halo effect”: Ozempic, Wegovy, and Zepbound actually work and are FDA-approved, which turned “peptide” into a household word and lent borrowed credibility to unrelated, unapproved compounds. The other is the timeless appeal of a simple fix, supercharged by online shopping and recommendation algorithms. Neither of these tells you anything about whether a specific gray-market peptide is safe or works.

How to weigh the evidence

When you read a claim about any specific peptide, picture the evidence on a ladder, from sturdiest to flimsiest. Roughly, it goes: systematic reviews and meta-analyses (studies that carefully pool together many other studies), then randomized controlled trials (RCTs — studies where people are randomly sorted into groups to compare a treatment against a control), then cohort studies, case-control studies, case series and reports, then animal studies, and finally test-tube (in vitro) work done in a dish. RCTs rank high because the random sorting evens out both known and unknown factors that could otherwise skew the results. Animal and lab studies are useful for coming up with ideas to test, but they are not proof that something helps people.

A real example makes this concrete. Most published research on BPC-157 traces back to a single research group, is overwhelmingly done in rodents, and includes almost no human trial evidence. The lead researcher holds patents and business interests that weren’t disclosed in the published papers, and the 2023 FDA action flagged possible safety risks. One formal review of the literature concluded the substance shouldn’t be used by humans without better human research. Plenty of citations exist — but they sit at the bottom of the evidence ladder, which is a very different thing from “proven in people.” Our How to Read a Peptide Study guide goes further on this.

A short checklist for any peptide you come across:

Is it FDA-approved for a specific use, or sold “for research use only”?
Where does the evidence sit — human RCTs, or rodents and anecdotes?
Is the evidence independent and repeated by others, or from a single group or never published?
Is it on the WADA banned list?
Are you getting pulled in by the GLP-1 halo? The fact that approved drugs work doesn’t carry over to an unrelated vial.

Bottom line

“Peptide” describes the structure of a molecule. It is not a category of safe or proven treatment. On one end sit decades of careful, FDA-approved medicine like insulin and the GLP-1 drugs. On the other sits a fast-growing gray market that borrows that credibility while selling unapproved compounds under a “research use only” label that does legal work, not safety work. The regulatory picture really is moving in 2026 — but advisory reviews and political statements are not the same as approval. The smart move is to ignore the word “peptide” as a sign of quality, and instead ask, every single time, where the actual human evidence stands for the specific compound in front of you. Use the Ledger for compound-by-compound evidence grades, and our guides on how to read a study, reading a certificate of analysis, and reconstitution and handling to go deeper.

Sources

New profiles and evidence updates only. No spam, and we never sell or share your email.